- Title
- A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.
- Creators
- IA McNeishA MichaelC TwelvesR GlasspoolMA AjazR MorrisonO XeniouR BrownK FisherC Blanc
- Contributors
- AMER SOC CLINICAL ONCOLOGY (Publisher)
- Publication Details
- JOURNAL OF CLINICAL ONCOLOGY, Vol.33(15)
- Conference
- Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (Chicago, IL, 29/05/2015 - 02/06/2015)
- Date published
- 20/05/2015
- Date submitted
- 17/05/2017
- Identifiers
- 99511298202346
- Academic Unit
- University of Surrey
- Resource Type
- Conference presentation
Conference presentation
A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.
JOURNAL OF CLINICAL ONCOLOGY, Vol.33(15)
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (Chicago, IL, 29/05/2015 - 02/06/2015)
20/05/2015
Metrics
28 Record Views